136 related articles for article (PubMed ID: 29156834)
1. Oncolytic reovirus inhibits angiogenesis through induction of CXCL10/IP-10 and abrogation of HIF activity in soft tissue sarcomas.
Carew JS; Espitia CM; Zhao W; Mita MM; Mita AC; Nawrocki ST
Oncotarget; 2017 Oct; 8(49):86769-86783. PubMed ID: 29156834
[TBL] [Abstract][Full Text] [Related]
2. Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus.
Kelly KR; Espitia CM; Zhao W; Wendlandt E; Tricot G; Zhan F; Carew JS; Nawrocki ST
Oncotarget; 2015 Dec; 6(38):41275-89. PubMed ID: 26513296
[TBL] [Abstract][Full Text] [Related]
3. The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer.
Mahalingam D; Patel S; Nuovo G; Gill G; Selvaggi G; Coffey M; Nawrocki ST
BMC Cancer; 2015 Jul; 15():513. PubMed ID: 26156229
[TBL] [Abstract][Full Text] [Related]
4. Targeting JAK/STAT Signaling Antagonizes Resistance to Oncolytic Reovirus Therapy Driven by Prior Infection with HTLV-1 in Models of T-Cell Lymphoma.
Islam S; Espitia CM; Persky DO; Carew JS; Nawrocki ST
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372612
[TBL] [Abstract][Full Text] [Related]
5. Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma.
Kelly KR; Espitia CM; Mahalingam D; Oyajobi BO; Coffey M; Giles FJ; Carew JS; Nawrocki ST
Oncogene; 2012 Jun; 31(25):3023-38. PubMed ID: 22002308
[TBL] [Abstract][Full Text] [Related]
6. Systemic administration of reovirus (Reolysin) inhibits growth of human sarcoma xenografts.
Hingorani P; Zhang W; Lin J; Liu L; Guha C; Kolb EA
Cancer; 2011 Apr; 117(8):1764-74. PubMed ID: 21472724
[TBL] [Abstract][Full Text] [Related]
7. Bio-distribution study of Reolysin® (pelareorep) through a single intravenous infusion in Sprague-Dawley rats.
Chakrabarty R; Tran H; Boulay I; Moran T; Parenteau A; Tavcar R; Bigras M; Hagerman A; Serl S; Thompson B; Coffey M
Invest New Drugs; 2013 Dec; 31(6):1476-86. PubMed ID: 24121993
[TBL] [Abstract][Full Text] [Related]
8. A Phase II Study of Pelareorep (REOLYSIN
Mahalingam D; Goel S; Aparo S; Patel Arora S; Noronha N; Tran H; Chakrabarty R; Selvaggi G; Gutierrez A; Coffey M; Nawrocki ST; Nuovo G; Mita MM
Cancers (Basel); 2018 May; 10(6):. PubMed ID: 29799479
[TBL] [Abstract][Full Text] [Related]
9. Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells.
Chen MC; Lee CF; Huang WH; Chou TC
Biochem Pharmacol; 2013 May; 85(9):1278-87. PubMed ID: 23416116
[TBL] [Abstract][Full Text] [Related]
10. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
Blancher C; Moore JW; Robertson N; Harris AL
Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776
[TBL] [Abstract][Full Text] [Related]
11. Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity.
Gong J; Sachdev E; Mita AC; Mita MM
World J Methodol; 2016 Mar; 6(1):25-42. PubMed ID: 27019795
[TBL] [Abstract][Full Text] [Related]
12. Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma.
Sivridis E; Giatromanolaki A; Gatter KC; Harris AL; Koukourakis MI;
Cancer; 2002 Sep; 95(5):1055-63. PubMed ID: 12209691
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of HIF-1alpha by oncolytic reovirus infection independently of VHL and p53.
Cho IR; Koh SS; Min HJ; Park EH; Ratakorn S; Jhun BH; Jeong SH; Yoo YH; Youn HD; Johnston RN; Chung YH
Cancer Gene Ther; 2010 May; 17(5):365-72. PubMed ID: 20075985
[TBL] [Abstract][Full Text] [Related]
14. CXC-chemokine-ligand-10 gene therapy efficiently inhibits the growth of cervical carcinoma on the basis of its anti-angiogenic and antiviral activity.
Wang LL; Chen P; Luo S; Li J; Liu K; Hu HZ; Wei YQ
Biotechnol Appl Biochem; 2009 Jul; 53(3):209-16. PubMed ID: 19257857
[TBL] [Abstract][Full Text] [Related]
15. The oncolytic virus, pelareorep, as a novel anticancer agent: a review.
Chakrabarty R; Tran H; Selvaggi G; Hagerman A; Thompson B; Coffey M
Invest New Drugs; 2015 Jun; 33(3):761-74. PubMed ID: 25693885
[TBL] [Abstract][Full Text] [Related]
16. Anti-angiogenic effects of ribonucleic acid interference targeting vascular endothelial growth factor and hypoxia-inducible factor-1alpha.
Forooghian F; Das B
Am J Ophthalmol; 2007 Nov; 144(5):761-8. PubMed ID: 17869204
[TBL] [Abstract][Full Text] [Related]
17. Low Molecular Weight Fucoidan Inhibits Tumor Angiogenesis through Downregulation of HIF-1/VEGF Signaling under Hypoxia.
Chen MC; Hsu WL; Hwang PA; Chou TC
Mar Drugs; 2015 Jul; 13(7):4436-51. PubMed ID: 26193287
[TBL] [Abstract][Full Text] [Related]
18. Reovirus-based therapy for cancer.
Kelly K; Nawrocki S; Mita A; Coffey M; Giles FJ; Mita M
Expert Opin Biol Ther; 2009 Jul; 9(7):817-30. PubMed ID: 19527106
[TBL] [Abstract][Full Text] [Related]
19. Reovirus double-stranded RNA genomes and polyI:C induce down-regulation of hypoxia-inducible factor 1α.
Hotani T; Tachibana M; Mizuguchi H; Sakurai F
Biochem Biophys Res Commun; 2015 May; 460(4):1041-6. PubMed ID: 25843794
[TBL] [Abstract][Full Text] [Related]
20. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
